The Potential of Cannabidiol for Acute Respiratory Distress Syndrome in COVID-19

    August 2023 in “ Current Pharmaceutical Design ”
    Saeed Azimi, Fatemeh Saghafi, Mohammad Hossein Mohammadi, Mohammad Hossein Moghimi, Seyed Ali Akhavan, Masoud Khataminia, Maria Shirvani, Seyed Mojtaba Sohrevardi, Tannaz Jamialahmadi, Adeleh Sahebnasagh, Adeleh Sahebnasagh, Amirhossein Sahebkar
    TLDR CBD may help manage severe lung issues in COVID-19 patients.
    This review explores the potential of cannabidiol (CBD), a non-psychotropic compound from Cannabis sativa, in managing acute respiratory distress syndrome (ARDS) in COVID-19 patients. ARDS and mortality in COVID-19 are primarily caused by a cytokine storm, an excessive release of cytokines. Early management of this storm with immunomodulators is crucial for improving patient survival rates. While some immunosuppressants like corticosteroids and tocilizumab have been studied, their use requires caution. CBD's anti-inflammatory properties may offer a promising alternative for managing ARDS in COVID-19 patients.
    Discuss this study in the Community →